Moody's Ratings (Moody's) has today affirmed Rheinmetall AG's (Rheinmetall) Baa2 long-term issuer rating. Concurrently, the rating agency has affirmed the company's P-2 short term issuer rating and its P-2 Commercial Paper rating. The outlook remains stable. RATINGS RATIONALE Today's ratin...
>Q1 in the end more in line with traditional seasonality - In a group pre-class call, the company indicated the seasonal pattern would in the end be fairly consistent with that of previous years, with Q4 potentially accounting for around 35% of FY 24 sales. The deferral of around € 0.4bn of sales from FY 23 to FY 24 will be only partially delivered in Q1 (c € 0.1bn est.), with the remainder of the truck deliveries expected more later in the year. We forecast sales of ...
>Un T1 finalement plus conforme à la traditionnelle saisonnalité - Lors d’un pre-close call groupé, la société a indiqué que la saisonnalité de l’exercice FY 24 serait finalement assez conforme à celle des autres années avec un T4 pouvant représenter de l’ordre de 35% du CA FY 24. Le décalage d’environ 0.4 Md€ de ventes de FY 23 à FY 24 ne sera que partiellement livré au T1 (c0.1 Md€e), le reliquat des livraisons de camions étant plutôt attendu plus tard dans l’exerci...
EQS-News: BRAIN Biotech AG / Key word(s): Miscellaneous BRAIN Biotech AG takes next step to optimize group structure 16.04.2024 / 11:20 CET/CEST The issuer is solely responsible for the content of this announcement. BRAIN Biotech AG takes next step to optimize group structure BRAIN Biotech Group will merge AnalytiCon Discovery GmbH into BRAIN Biotech AG in order to further optimize and simplify the Group structure. Zwingenberg, Germany, 16 April 2024 – The Management Board of BRAIN Biotech AG, with the approval of the Supervisory Board, has resolved to merge AnalytiCon ...
EQS-News: BRAIN Biotech AG / Schlagwort(e): Sonstiges BRAIN Biotech AG unternimmt nächsten Schritt zur Optimierung der Gruppenstruktur 16.04.2024 / 11:20 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. BRAIN Biotech AG unternimmt nächsten Schritt zur Optimierung der Gruppenstruktur Die BRAIN Biotech Gruppe wird zur weiteren Optimierung und Vereinfachung der Gruppenstruktur die AnalytiCon Discovery GmbH mit der BRAIN Biotech AG verschmelzen. Zwingenberg, 16. April 2024 – Der Vorstand der BRAIN Biotech AG hat mit Zustimmung des Aufsic...
A director at Rheinmetall AG bought 600 shares at 520.805EUR and the significance rating of the trade was 81/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...
After very strong results during 2021 and 2022 on the back of industry tailwinds due to supply chain disruptions, IMCD maintained a relatively steady operating performance over 2023 despite a clear normalisation of end-market demand within Industries. Notwithstanding these industry pressures, IMCD was able to offset the negative organic growth over 2023 (-6.4%) with its acquisitory power, stabilising growth for the year (excl. FX impact). We believe that IMCD is ready to resume its up...
>Neutre vs Surperformance – OC relevé à 520 € - Suite au fort relèvement de nos estimations (20.9% en 2024 y compris rattrapage des 420 M€ de ventes manquantes en 2023, 23% en 2025 et 33.9% en 2026), nous relevons notre OC à 520 € (basé sur une moyenne DCF et SOP 2026). Toutefois, après une progression de 63% YtD contre +27% pour notre indice Défense Europe, le potentiel du titre nous semble aujourd’hui plus limité. Le consensus a désormais intégré une forte accéléra...
>Neutral vs Outperform – target price raised to € 520 - Following the sharp upward revision to our estimates (20.9% in 2024 including the catch-up of € 420m in missing sales in 2023, 23% in 2025 and 33.9% in 2026), we are raising our target price to € 520 (based on an average of the DCF and SOTP for 2026). However, after growth of 63% YTD vs +27% for our Europe Defence index, the stock’s upside now looks more limited to us. The consensus has now factored in a sharp ...
Banks tick all the boxes in the market’s current configuration: search for discounted sectors, cyclical momentum, sectors driven by long-term interest rates that remain high and shareholder returns through very high dividend yields. Technical analysis reveals a strong conviction since early March, and this should continue. We prefer banks in southern Europe, where the macro outlook is brighter. Alongside CaixaBank, which we are maintaining in our list of European Large Cap stocks, we ...
Les banques cochent toutes les cases de la configuration de marché actuelle : recherche de secteurs décotés, momentum cyclique, secteurs portés par des taux longs qui restent hauts, retour à l’actionnaire via un très haut dividend yield. L’analyse technique montre une forte conviction depuis début mars, qui devrait se poursuivre. Nous favorisons les banques du sud de l’Europe, à la macro plus avenante. Aux côtés de CaixaBank, que nous conservons dans notre liste de valeurs Large Caps ...
EQS-News: BRAIN Biotech AG / Schlagwort(e): Kooperation/Nachhaltigkeit Getränke aus Weinblättern: Nachhaltiger Trinkgenuss auf Basis landwirtschaftlicher Seitenströme 14.03.2024 / 09:00 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Getränke aus Weinblättern: Nachhaltiger Trinkgenuss auf Basis landwirtschaftlicher Seitenströme BRAIN Biotech, Tropical Viticulture Consultants, Zukunftsweine und die Provadis Hochschule entwickeln gemeinsam nachhaltige, alkoholfreie Getränke aus landwirtschaftlichen Seitenströmen Konsortium nutzt Vorte...
EQS-News: BRAIN Biotech AG / Key word(s): Alliance/Sustainability Beverages made from vine leaves: Sustainable drinking pleasure based on agricultural side streams 14.03.2024 / 09:00 CET/CEST The issuer is solely responsible for the content of this announcement. Beverages made from vine leaves: Sustainable drinking pleasure based on agricultural side streams BRAIN Biotech, Tropical Viticulture Consultants, Zukunftsweine and Provadis Hochschule jointly develop sustainable, non-alcoholic beverages from agricultural side streams Consortium reaps benefits of new grape varie...
>FY 23 print pretty much in line with estimates - At first glance, FY 2023 results came in broadly in line with expectations with operating results at € 918m (Vara Consensus: € 922.8m) for sales of € 7,176m, up by 10.6% l-f-l, representing a margin of 12.8% (+80bp). EBIT pre PPA reached € 968m. As a reminder, about € 0.4bn of sales have been pushed into FY 24 in trucks and weapon & ammunitions. Operating margins in the various segments were also broadly in line with e...
>FY 23 print pretty much in line with estimates - At first glance, FY 2023 results came in broadly in line with expectations with operating results at € 918m (Vara Consensus: € 922.8m) for sales of € 7,176m, up by 10.6% l-f-l, representing a margin of 12.8% (+80bp). EBIT pre PPA reached € 968m. As a reminder, about € 0.4bn of sales have been pushed into FY 24 in trucks and weapon & ammunitions. Operating margins in the various segments were also broadly in line with e...
EQS-News: BRAIN Biotech AG / Key word(s): AGM/EGM Results of the Annual General Meeting 2024 for the financial year 2022/23 of BRAIN Biotech AG 12.03.2024 / 17:17 CET/CEST The issuer is solely responsible for the content of this announcement. Results of the Annual General Meeting 2024 for the financial year 2022/23 of BRAIN Biotech AG Face-to-face event at the Zwingenberg site Executive Board and Supervisory Board approved by a clear majority Silent partnership with the State of Hesse approved by a very large majority Zwingenberg, Germany, 12 March 2024 – At today´s An...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.